Fundraising FoxJanus Henderson Investors — 2024 Investments
6 investments dated 2024 · listed companies and verified rows first · show all
Aktis Oncology discovers and develops targeted radiopharmaceuticals for treating solid tumors.
BiotechHealthtechMedical DevicesBoston, US
Todd Foley(Co-founder and Chairman)inPatrick Baeuerle(Co-founder & Advisor)inShulamit Ron-Bigger(Executive Officer)inKyle D. Kuvalanka(Chief Financial Officer)inAkos Czibere(Chief Medical Officer)inPaul L. Feldman(Chief Scientific Officer)in
Co-investorsAndreessen HorowitzEcoR1 CapitalMPM BioImpactMRL Ventures FundPappas CapitalRA Capital+5 more
Monopar Therapeutics is a clinical-stage biotechnology company developing radiopharmaceuticals for oncology and a treatment for Wilson Disease, a rare genetic disorder.
BiotechHealthtechMedical DevicesLake Forest, US
Chandler D. Robinson(Executive Officer, Director, Promoter)inChristopher M. Starr(Executive Officer, Director)Andrew P. Mazar(Executive Officer, Director)
BoardMichael J. Brown(Director)
Co-investorsRA Capital
Alpha-9 Oncology develops radiopharmaceuticals for cancer treatment, with a portfolio of molecules in clinical and preclinical development.
BiotechDigital HealthMedical DevicesVancouver, CA
François Bénard(Founder)Kuo-Shyan Lin(Founder)David Perrin(Founder)
Co-investorsAndreessen HorowitzAscenta CapitalDelos CapitalFrazier Life SciencesGeneral CatalystLightspeed Venture Partners+9 more
.png)
Asher Bio develops selective immunotherapy drugs that target specific immune cell types to promote beneficial effects while minimizing toxicity.
BiotechHealthtechMedical DevicesSan Francisco, US
Ivana Djuretic(Founder)inAndy Yeung(Drug discovery)inYik Andy Yeung(Executive Officer, Director, Promoter)
Co-investorsEmles Venture PartnersGoAhead VenturesMission Bay CapitalMission BiocapitalRA CapitalWellington Management+9 more
Metsera was a clinical-stage biotechnology company developing injectable and oral medicines for obesity and metabolic diseases, including next-generation GLP-1 and amylin-based therapies.
BiotechHealthtechMedical DevicesNew York, US
Clive A. Meanwell(Director)Christopher J. Visioli(Executive Officer)inBrian Hubbard(Executive Officer)inChristopher Whitten Bernard(Executive Officer, Director)Steven Marso(Executive Officer)Clive Meanwell(Founder)
Co-investorsAlpha Wave GlobalARCH Venture PartnersF-Prime CapitalGV (Google Ventures)RA CapitalSoftBank Vision Fund+5 more
nChroma Bio develops in vivo targeted delivery and genetic engineering technologies for genetic medicine applications.
BiotechDeep TechMedical DevicesBoston, US
Luke Gilbert, PhD(Founder)Keith Joung, MD, PhD(Founder)David Liu, PhD(Founder)Angelo Lombardo, PhD(Founder)Luigi Naldini, MD, PhD(Founder)Jonathan Weissman, PhD
Co-investorsAtlas VentureNewpath Partners5AM VenturesARCH Venture PartnersDCVC (Data Collective)F-Prime Capital+11 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.